Menarini Asia-Pacific and Pharmacosmos partner to bring first-in-class oncology supportive care therapy Cosela® to Asian patients

SINGAPORE , July 21, 2026 /PRNewswire/ -- Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela ® (trilaciclib) across its Asia-Pacific markets.

Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect that damages bone marrow, significantly impacting its hematopoietic function (or its ability to produce healthy blood cells). For patients with extensive-stage small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment, yet it is a major dose limiting complication that can disrupt treatment and compromise outcomes [1] . Cosela ® is a first-in-class prophylactic therapy [2] FDA approved to help protect bone marrow from CIM, addressing a significant unmet need in oncology supportive care for these patients.

Under the agreement, Menarini Asia-Pacific will manage all aspects of registration, reimbursement, commercialisation and distribution of Cosela ® in Australia, Hong Kong/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.

"Cosela ® represents an important advancement in oncology supportive care and the kind of innovation that can make a meaningful difference for patients," said Glen Godresse, Chief Executive Officer of Menarini Asia-Pacific . "Partnerships like this are central to Menarini Asia-Pacific's mission of helping innovative therapies reach patients with our end-to-end capabilities. We look forward to working with Pharmacosmos to expand access to Cosela ® across our region and help more patients benefit from this first-in-class treatment."

"As we looked to expand access to Cosela ® across Asia-Pacific, we wanted a long-term partner with the capabilities to support every stage of the journey, from registration through to commercialization and patient access," said Klaus Abel, Vice President, Global Commercial Partnerships, Pharmacosmos . "Menarini Asia-Pacific's deep local market expertise and patient-focused approach make them the ideal partner to bring this important innovation to patients across the region."

Cosela ® is currently marketed in the United States and China and is under registration in Europe. Subject to regulatory approvals, the first Asia-Pacific launch is anticipated in Hong Kong in 2028, followed by other markets thereafter.

The partnership builds on an existing relationship between the two companies, following a 2024 agreement to commercialise innovative iron infusion Monofer ® across key Asia-Pacific markets.

| |
| --- |
| References |
| [1]. Weiss JM et al. Managing Chemotherapy-Induced Myelosuppression with Trilaciclib. Clin Lung Cancer. 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/33895103/ |
| [2]. Alqahtani S, Alzahrani A, Alhakamy NA, et al. Trilaciclib: a first-in-class CDK4/6 inhibitor with dual roles in myelopreservation and cell cycle regulation. Medicinal Chemistry Research. 2024. Available at: https://link.springer.com/article/10.1007/s00044-024-03288-y |

This press release is intended for media and investor relations purposes only and does not constitute medical advice, product promotion or a recommendation for the use of any medicinal product. Cosela ® (trilaciclib) is subject to local regulatory approvals.

About Menarini Asia-Pacific Menarini Asia-Pacific is a member of the Menarini Group, a leading international pharmaceutical and diagnostic company with a heritage of over 135 years and over 17,000 employees in 140 countries. Here in Asia-Pacific, Menarini's vision is to be a leading provider of important healthcare brands to improve the lives of people. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval, and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory, Gastroenterology, Cardio-metabolic, Oncology/Specialty Care and Men's Health.

“This is a company press release that is not part of editorial content. No journalist of The Hindu was involved in the publication of this release.”

Published - July 21, 2026 08:30 am IST